Table 2 Comparison of the demographic and clinical characteristics between patients with and without CMV disease
Variables | Patients with CMV disease (n = 50) | Patients without CMV disease (n = 258) | P–value |
|---|---|---|---|
Male, n (%) | 29(58.0) | 146 (56.6) | 0.87 |
Age, year | 53.4 ± 13.7 | 54.8 ± 14.4 | 0.94 |
Body mass index, kg/m2 | 20.0 ± 3.5 | 20.6 ± 4.0 | 0.74 |
Type of transplantation, n (%) | 0.61 | ||
Bilateral lungs | 18 (36) | 90 (34.9) | |
Single lung | 28 (56) | 136 (52.7) | |
Heart–lung | 3 (6) | 14 (5.4) | |
Heart | 1 (2) | 18 (7.0) | |
Valganciclovir prophylaxis, n (%) | 7 (14) | 91 (35.3) | 0.02 |
Duration of prophylaxis, day | 39 (range, 12–193) | 33 (range, 11–129) | 0.04 |
D+/R−, n (%) | 8 (16) | 11 (4.26) | 0.004 |
r–ATG > 2 mg/kg, n (%) | 18 (36) | 35 (13.6) | 0.002 |
Basiliximab, n (%) | 6 (12) | 39 (15.1) | 0.62 |
Plasma CMV viral load, UI/ml median (IQR) | 31,500 (17,325–124,250) | 2520 (1125–6325) | < 0.001 |